Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
Giving erlotinib, paclitaxel, and carboplatin together with radiation therapy before surgery
may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Giving these treatments after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase I/II trial is studying the best dose of erlotinib and the side effects of
erlotinib, paclitaxel, and carboplatin when given together with radiation therapy and to see
how well they work in treating patients who are undergoing surgery for stage III non-small
cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Case Comprehensive Cancer Center Nathan Pennell, MD, PhD